Grufity logoGrufity logo

TMO

563.00USD-1.56(-0.28%)Market Closed

Thermo Fisher Scientific Inc

Market Summary

USD563.00-1.56Market Closed
-0.28%

TMO Alerts

TMO Stock Price

RSI Chart

Valuation

Market Cap

197.5B

Price/Earnings

26.51

Price/Sales

4.61

Price/Cashflow

22.35

MarketCap/EBT

23.24

Price/Sales

Profitability

EBT Margin

19.85%

Return on Equity

17.62%

Return on Assets

8.23%

Fundamentals

Revenue

Revenue (TTM)

44.2B

Revenue Y/Y

14.44%

Revenue Q/Q

-2.67%

Earnings

Earnings (TTM)

7.5B

Earnings Y/Y

-8.8%

Earnings Q/Q

-24.86%

Price Action

52 Week Range

672.34
(Low)(High)

Last 7 days

2.1%

Last 30 days

14.7%

Last 90 days

3.6%

Trailing 12 Months

-10.2%

Financial Health

Current Ratio

1.65

Debt/Equity

0.71

Debt/Cashflow

0.29

Investor Care

Dividend Yield

0.22%

Dividend/Share (TTM)

1.16

Buy Backs (1Y)

0.25%

Diluted EPS (TTM)

17.79

Peers (Alternatives to Thermo Fisher Scientific)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
197.5B
44.2B
14.67% -10.25%
26.51
4.61
13.08% -13.35%
36.7B
4.7B
3.69% -38.80%
-1.9K
7.81
9.79% -558.28%
28.5B
3.9B
19.96% -3.97%
34.68
7.36
7.75% 11.02%
18.1B
2.9B
17.46% 4.00%
25.81
6.25
8.61% 6.30%
MID-CAP
9.1B
2.5B
9.56% -17.65%
33.17
3.67
6.09% 1.70%
SMALL-CAP
2.0B
137.0M
31.93% -50.56%
-9.53
14.05
12.61% -709.53%
1.1B
159.7M
14.14% -65.84%
-4.68
6.81
19.67% -35.56%
942.2M
496.8M
58.31% -64.07%
-6.42
1.93
2.51% -434.48%
661.5M
23.3M
-6.28% -43.67%
-6.25
28.36
76.56% -106.44%
413.2M
110.0M
30.54% -66.08%
-5.25
3.72
3.37% -106.72%
372.0M
132.7M
-1.39% -83.46%
-19.64
2.76
31.03% -107.73%
187.1M
42.4M
-33.92% -78.27%
-2.44
4.51
30.40% -43.67%
109.5M
118.0M
6.72% -56.67%
-29.97
0.91
0.97% -269.58%
105.9M
68.8M
4.79% -62.04%
-3.75
1.53
5.65% 26.86%

Financials for Thermo Fisher Scientific

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue3.1%44,16742,82041,12339,21139,059
  S&GA Expenses2.3%8,9728,7688,4588,0077,806
  R&D Expenses0%1,4721,4721,4501,4061,390
Earnings Before Taxes-6.7%7,9268,4988,6288,8419,865
Net Income-2.1%7,4517,6127,7288,568
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets0.0%90,53690,57992,74795,12373,600
  Current Assets6.6%19,29918,10018,77620,11324,724
    Cash Equivalents54.6%2,9191,8882,7524,47712,027
  Inventory1.0%5,7225,6685,4835,0514,906
  Net PPE1.2%8,6288,5298,4488,3337,049
  Goodwill-1.4%40,48841,06641,72141,92426,909
  Current Liabilities1.1%11,11810,99712,07013,4367,753
  Long Term Debt-3.7%28,94130,06033,06034,67021,598
Shareholder's Equity3.0%43,54942,29340,95640,79338,710
  Retained Earnings3.5%40,45239,07437,52835,43133,876
  Additional Paid-In Capital0.8%16,59616,46716,29216,17415,960
Accumulated Depreciation-4,260----
Shares Outstanding0%392392394--
Minority Interest-3.3%59616262-
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-8.1%8,1248,8379,5369,31210,194
  Share Based Compensation9.2%309283257230204
Cashflow From Investing0.3%-20,326.00-20,397.00-20,604.00-21,932.00-3,866.00
Cashflow From Financing-49.4%3,2666,4578,2866,581-1,935.00
  Dividend Payments3.8%441425411395379
  Buy Backs0%2,0002,0002,0002,0002,000

Risks

What is the probability of a big loss on TMO?

15%


Probability that Thermo Fisher Scientific stock will be more than 20% underwater in next one year

0%


Probability that Thermo Fisher Scientific stock will be more than 30% underwater in next one year.

0%


Probability that Thermo Fisher Scientific stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TMO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Thermo Fisher Scientific was unfortunately bought at previous high price.

Returns

Cumulative Returns on TMO

24.8%


10-Year Cumulative Returns

22.7%


7-Year Cumulative Returns

24.3%


5-Year Cumulative Returns

21.8%


3-Year Cumulative Returns

What are the long-term rolling returns for TMO?

FIve years rolling returns for Thermo Fisher Scientific.

Which funds bought or sold TMO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
ADDED
1.15
-22,722
401,000
0.25%
2022-11-23
Invst, LLC
SOLD OFF
-100
-206,000
-
-%
2022-11-23
Toroso Investments, LLC
ADDED
7.5
15,000
4,225,000
0.18%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
29,342,000
29,342,000
0.34%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
85.09
8,700,000
20,649,000
0.62%
2022-11-22
Dash Acquisitions Inc.
-
-
-133,000
7,896,000
4.41%
2022-11-22
CVA Family Office, LLC
-
-
-187,000
716,000
0.19%
2022-11-22
IHT Wealth Management, LLC
-
-
377,000
1,712,000
0.13%
2022-11-21
DEARBORN PARTNERS LLC
-
-
-14,000
270,000
0.01%
2022-11-21
ST GERMAIN D J CO INC
-
-
-
284,000
0.02%

1–10 of 47

Latest Funds Activity

Are funds buying TMO calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own TMO

Thermo Fisher Scientific News

MarketWatch

Waters Corp. stock outperforms market on strong trading day.24 hours ago

TMO Fair Value

Recent SEC filings of Thermo Fisher Scientific

View All Filings
Date Filed Form Type Document
Nov 22, 2022
CERT
CERT
Nov 21, 2022
8-A12B
8-A12B
Nov 21, 2022
8-K
Current Report
Nov 18, 2022
4
Insider Trading
Nov 15, 2022
424B5
Prospectus Filed
Nov 15, 2022
424B5
Prospectus Filed
Nov 14, 2022
FWP
Prospectus Filed
Nov 14, 2022
FWP
Prospectus Filed
Nov 14, 2022
8-K
Current Report
Nov 14, 2022
424B5
Prospectus Filed

Latest Insider Trading transactions for TMO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-17
CASPER MARC N
SOLD
-3,946,720
526.23
-7,500
Chairman & CEO
2022-11-16
CASPER MARC N
SOLD
-4,025,200
536.693
-7,500
Chairman & CEO
2022-11-11
CASPER MARC N
SOLD
-5,378,660
537.866
-10,000
Chairman & CEO
2022-11-10
CASPER MARC N
SOLD
-5,152,740
515.274
-10,000
Chairman & CEO
2022-11-07
CASPER MARC N
ACQUIRED
1,051,140
129.77
8,100
Chairman & CEO
2022-11-07
CASPER MARC N
SOLD
-3,994,590
493.159
-8,100
Chairman & CEO
2022-11-04
CASPER MARC N
SOLD
-4,889,420
488.942
-10,000
Chairman & CEO
2022-11-04
CASPER MARC N
ACQUIRED
1,297,700
129.77
10,000
Chairman & CEO
2022-11-03
CASPER MARC N
SOLD
-3,997,060
487.446
-8,200
Chairman & CEO
2022-11-03
CASPER MARC N
SOLD
-865,070
480.594
-1,800
Chairman & CEO

1–10 of 50

Marc N. Casper
65535
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.

TMO Income Statement

2022-10-01
Consolidated Statement of Income (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Oct. 01, 2022
Oct. 02, 2021
Oct. 01, 2022
Oct. 02, 2021
Revenues    
Revenues$ 10,677$ 9,330$ 33,465$ 28,509
Costs and operating expenses:    
Selling, general and administrative expenses2,2082,0046,6945,729
Research and development expenses3513511,0801,014
Restructuring and other costs331859151
Total costs and operating expenses8,9677,05226,93321,019
Operating income1,7102,2786,5327,490
Interest income68912232
Interest expense(173)(128)(457)(375)
Other income/(expense)(4)18(139)(168)
Income before income taxes1,6012,1776,0586,979
Provision for income taxes(31)(271)(530)(906)
Equity in earnings/(losses) of unconsolidated entities(72)(3)(142)(4)
Net income1,4981,9035,3866,069
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest31122
Net income$ 1,495$ 1,902$ 5,374$ 6,067
Earnings per share attributable to Thermo Fisher Scientific Inc.    
Basic (in dollars per share)$ 3.82$ 4.83$ 13.72$ 15.41
Diluted (in dollars per share)$ 3.79$ 4.79$ 13.62$ 15.29
Weighted average shares    
Basic (in shares)392394392394
Diluted (in shares)395397395397
Product revenues    
Revenues    
Revenues$ 6,583$ 7,360$ 21,603$ 22,430
Costs and operating expenses:    
Cost of revenues3,4943,29810,5659,977
Service revenues    
Revenues    
Revenues4,0941,97011,8626,079
Costs and operating expenses:    
Cost of revenues$ 2,881$ 1,381$ 8,535$ 4,148

TMO Balance Sheet

2022-10-01
Consolidated Balance Sheet (Unaudited) - USD ($)
Oct. 01, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 2,919,000,000$ 4,477,000,000
Accounts receivable, less allowances of $185 and $1507,671,000,0007,977,000,000
Inventories5,722,000,0005,051,000,000
Contract assets, net1,248,000,000968,000,000
Other current assets1,739,000,0001,640,000,000
Total current assets19,299,000,00020,113,000,000
Property, plant and equipment, net8,628,000,0008,333,000,000
Acquisition-related intangible assets, net17,813,000,00020,113,000,000
Other assets4,308,000,0004,640,000,000
Goodwill40,488,000,00041,924,000,000
Total assets90,536,000,00095,123,000,000
Current liabilities:  
Short-term obligations and current maturities of long-term obligations1,010,000,0002,537,000,000
Accounts payable2,471,000,0002,867,000,000
Accrued payroll and employee benefits1,864,000,0002,427,000,000
Contract liabilities2,567,000,0002,655,000,000
Other accrued expenses3,206,000,0002,950,000,000
Total current liabilities11,118,000,00013,436,000,000
Deferred income taxes3,140,000,0003,837,000,000
Other long-term liabilities4,401,000,0004,540,000,000
Long-term obligations28,150,000,00032,333,000,000
Redeemable noncontrolling interest119,000,000122,000,000
Thermo Fisher Scientific Inc. shareholders’ equity:  
Preferred stock, $100 par value, 50,000 shares authorized; none issued00
Common stock, $1 par value, 1,200,000,000 shares authorized; 440,352,770 and 439,154,741 shares issued440,000,000439,000,000
Capital in excess of par value16,596,000,00016,174,000,000
Retained earnings40,452,000,00035,431,000,000
Treasury stock at cost, 48,157,213 and 44,720,112 shares(11,011,000,000)(8,922,000,000)
Accumulated other comprehensive items(2,928,000,000)(2,329,000,000)
Total Thermo Fisher Scientific Inc. shareholders’ equity43,549,000,00040,793,000,000
Noncontrolling interests59,000,00062,000,000
Total equity43,608,000,00040,855,000,000
Total liabilities, redeemable noncontrolling interest and equity$ 90,536,000,000$ 95,123,000,000